Effectiveness of adjunctive clindamycin in β-lactam antibiotic-treated patients with invasive β-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study

Real-world data(n=1956) suggest increased use of adjunctive clindamycin for invasive group A β-haemolytic streptococcal (iGAS)-but not invasive non-group A/B β-haemolytic streptococcal (iNABS) infections could improve outcomes, even in patients without shock/necrotising fasciitis

SPS commentary:

In the iGAS cohort, in-hospital mortality in propensity-matched patients who received adjunctive clindamycin (18 [6·5%] of 277 patients) was significantly lower than in those who did not (55 [11·0%] of 500 patients; aOR 0·44 [95% CI 0·23–0·81]).

The Lancet Infectious Diseases